about
Investigations on the synthesis and pharmacological properties of N-substituted derivatives of 4-alkoxy-6-methyl-1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dionesAntidepressant- and Anxiolytic-Like Effects of New Dual 5-HT₁A and 5-HT₇ Antagonists in Animal ModelsAnalgesic, antiallodynic, and anticonvulsant activity of novel hybrid molecules derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide in animal models of pain and epilepsy.Antinociceptive activity of transient receptor potential channel TRPV1, TRPA1, and TRPM8 antagonists in neurogenic and neuropathic pain models in mice.Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives.3-[4-(3-Trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one and pregabalin attenuate tactile allodynia in the mouse model of chronic constriction injury.Design, synthesis and anticonvulsant activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-1-yl)-propanamides and -butanamides.Synthesis and evaluation of anticonvulsant properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and its 3-methyl-, 3-isopropyl, and 3-benzhydryl analogs.Evaluation of anticonvulsant and antinociceptive properties of new N-Mannich bases derived from pyrrolidine-2,5-dione and 3-methylpyrrolidine-2,5-dione.Development of an in-vivo active reversible butyrylcholinesterase inhibitor.Aryl-1,3,5-triazine ligands of histamine H4 receptor attenuate inflammatory and nociceptive response to carrageen, zymosan and lipopolysaccharide.Synthesis and activity of newly designed aroxyalkyl or aroxyethoxyethyl derivatives of piperazine on the cardiovascular and the central nervous systems.The role of serotonergic, adrenergic and dopaminergic receptors in antidepressant-like effect.The role of glutamatergic, GABA-ergic, and cholinergic receptors in depression and antidepressant-like effect.HBK-7 - A new xanthone derivative and a 5-HT1A receptor antagonist with antidepressant-like properties.Influence of analgesic active 3-[4-(3-trifluoromethyl-phenyl)-piperazin-1-yl]-dihydrofuran-2-one on the antioxidant status, glucose utilization and lipid accumulation in some in vitro and ex vivo assays.The role of melatonin, neurokinin, neurotrophic tyrosine kinase and glucocorticoid receptors in antidepressant-like effect.Evaluation of antidepressant-like and anxiolytic-like activity of purinedione-derivatives with affinity for adenosine A2A receptors in mice.Chemically Homogenous Compounds with Antagonistic Properties at All α1-Adrenoceptor Subtypes but not β1-Adrenoceptor Attenuate Adrenaline-Induced Arrhythmia in RatsHypotensive effect of alpha-lipoic acid after a single administration in rats.Synthesis and adrenolytic activity of new propanolamines.Synthesis and adrenolytic activity of 1-(1H-indol-4-yloxy)-3-(2-(2-methoxy phenoxy)ethylamino)propan-2-ol analogs and its enantiomers. Part 2.Synthesis, antiarrhythmic, and antihypertensive effects of novel 1-substituted pyrrolidin-2-one and pyrrolidine derivatives with adrenolytic activity.Antiarrhythmic properties of some 1,4-disubstituted piperazine derivatives with α1-adrenoceptor affinities.Preparation of novel derivatives of pyridothiazine-1,1-dioxide and their CNS and antioxidant properties.Are anti-inflammatory properties of lipoic acid associated with the formation of hydrogen sulfide?Antinociceptive effects of novel A2B adenosine receptor antagonists.[Pharmacotherapy of Parkinson's disease: progress or regress?].Bioactivation of nitroglycerin to nitric oxide (NO) and S-nitrosothiols in the rat liver and evaluation of the coexisting hypotensive effect.Synthesis and evaluation of in vivo activity of diphenylhydantoin basic derivatives.Design, synthesis and pharmacological evaluation of new 1-[3-(4-arylpiperazin-1-yl)-2-hydroxy-propyl]-3,3-diphenylpyrrolidin-2-one derivatives with antiarrhythmic, antihypertensive, and alpha-adrenolytic activity.Preliminary evaluation of pharmacological properties of some xanthone derivatives.Biphenyloxy-alkyl-piperidine and azepane derivatives as histamine H3 receptor ligands.Evaluation of anxiolytic-like, anticonvulsant, antidepressant-like and antinociceptive properties of new 2-substituted 4-hydroxybutanamides with affinity for GABA transporters in mice.The role of lipoic acid in prevention of nitroglycerin tolerance.Biofunctional studies of new 2-methoxyphenylpiperazine xanthone derivatives with α₁-adrenolytic properties.Synthesis, alpha 1-adrenoceptor antagonist activity, and SAR study of novel arylpiperazine derivatives of phenytoin.Synthesis and evaluation of some xanthone derivatives for anti-arrhythmic, hypotensive properties and their affinity for adrenergic receptors.Antiarrhythmic activity of some xanthone derivatives with β1-adrenoceptor affinities in rats.The effect of GABA transporter 1 (GAT1) inhibitor, tiagabine, on scopolamine-induced memory impairments in mice.
P50
Q28213292-3CC883BD-7DA6-4908-B283-7B3B2DCDBF40Q28550792-1F908F2A-589D-402E-AA86-F534E62C6F89Q33621804-74B1C08A-1204-4B1C-B228-4C19D00E1B71Q35170603-45482DE8-3E3F-443D-8D87-4F2C6B03EAE4Q35600431-567C916E-0F54-4483-86DF-5D989A61CD8DQ35637859-E28B6132-8BFB-4127-B4F8-738E16DEC7B2Q36025817-95376BD4-F6D7-4E45-BE47-DEE9B3A6C0E1Q36281847-2E081FEC-BF11-4365-A9D7-77346D2B2C8EQ36568597-FCE43F57-B068-4BAA-8D89-05057C9D5449Q37522451-ADBBFE65-AE6F-42BD-939D-702F59EF2867Q37553620-ACD3A590-C7D5-43FC-B901-5D23971C296FQ38737646-6A366ED3-8A18-4CF6-90A5-FECD0A0F4116Q38753146-965F9DF9-8F8D-4B8D-AC24-965E0BC571B9Q38753164-F65BD9E5-C6D5-4328-9786-E3EA7DADBA1EQ38873393-AE6691A2-58F5-4EFD-B4E2-4681249A3814Q39037121-C1EA2185-D1D3-4207-800A-811004541620Q39212534-88C6455A-7C3D-4FC8-9760-BAABDE94F911Q39334754-FF2F3675-0495-4F5A-A160-D7F5434D926DQ42058859-0DBACE3F-0B8E-49ED-8CD3-5C8591B3D8CDQ42089891-EC802459-2A69-441A-A30C-2724EDE501A9Q42958817-78CA9E4D-022E-4E46-AEC1-A04B375BB60AQ43300596-BCD99423-1421-4E62-8669-815180B47F7CQ43921800-EF7A376E-C4CD-4728-9DA4-4CB5B34F0392Q44133444-201C9292-A1F4-4855-ADC1-C6B13C629CFDQ44183551-0DFA4709-1D1F-4498-AAF6-530B576770EBQ44349321-20B0E303-BCED-445B-AFA5-347F37B38A3DQ44620924-BEBE8B6F-88F7-4578-9BAA-116A95C6B5DDQ44728288-494C6D00-470E-453C-9D13-62276D713384Q45018836-362C9094-FF92-4A74-9BD1-33B1803CF4D4Q45168301-BEF557DE-8E3A-4FEE-B309-33C4EBBFF2EBQ46008778-A2A17BC0-A8C3-42B7-88E9-E9066947609EQ46170868-AF9FBB65-B5C5-4A91-B43C-D1A42989A704Q46336024-4C8DC25B-490C-4E70-94EF-970D2D7F0630Q46468534-5B75464F-F999-43C9-8957-53D3797D5C34Q46490928-C741371F-7B09-4DBC-B190-931AE6C34C3EQ46526511-9F210BEA-C5BA-460C-BD4E-8F3979DE3F3EQ46587620-DC38C5D6-7D0B-4C32-B218-882B0F572EBAQ46778801-948A7080-280E-482C-B987-87A9C5B8260DQ46903664-A8DE1824-4CD4-4C12-B7B3-B09BD10A878BQ47604667-D21A8B83-7A0B-47F3-9545-65394C311CB1
P50
description
researcher ORCID ID = 0000-0001-8487-9945
@en
wetenschapper
@nl
name
Barbara Filipek
@ast
Barbara Filipek
@ca
Barbara Filipek
@cs
Barbara Filipek
@en
Barbara Filipek
@es
Barbara Filipek
@gl
Barbara Filipek
@hr
Barbara Filipek
@hsb
Barbara Filipek
@it
Barbara Filipek
@nl
type
label
Barbara Filipek
@ast
Barbara Filipek
@ca
Barbara Filipek
@cs
Barbara Filipek
@en
Barbara Filipek
@es
Barbara Filipek
@gl
Barbara Filipek
@hr
Barbara Filipek
@hsb
Barbara Filipek
@it
Barbara Filipek
@nl
altLabel
Barbara Maria Filipek
@pl
prefLabel
Barbara Filipek
@ast
Barbara Filipek
@ca
Barbara Filipek
@cs
Barbara Filipek
@en
Barbara Filipek
@es
Barbara Filipek
@gl
Barbara Filipek
@hr
Barbara Filipek
@hsb
Barbara Filipek
@it
Barbara Filipek
@nl
P214
P1153
7004160991
P1412
P1559
Barbara Filipek
@pl
P21
P214
P27
P31
P3124
P496
0000-0001-8487-9945
P734
P7859
viaf-165060800